english.prescrire.org > Spotlight > Archives : 2020 > VEGF inhibitors: arterial aneurysm and dissection

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2020 : 1 | 30 | 60

In the September issue of Prescrire International. VEGF inhibitors: arterial aneurysm and dissection

FREE DOWNLOAD Drugs that target vascular endothelial growth factor (VEGF) inhibit angiogenesis and are mainly used to treat diseases involving vascular proliferation, in particular cancer and certain eye conditions (by intravitreal administration). They can provoke cardiovascular disorders such as hypertension, heart failure and arterial or venous thromboembolic events.
Full text available for free download.

Abstract

  • Cases of arterial aneurysm or dissection have been reported with VEGF inhibitors, such as beva­cizumab, used to treat cancer. Systemic administration and hypertension, a known adverse effect of these anti-angiogenic drugs, are risk factors.
     
  • In practice, monitoring is warranted for patients treated with VEGF inhibitors, especially those with cardiovascular risk factors.

©Prescrire 1 September 2020

Source: "VEGF inhibitors: arterial aneurysm and dissection" Prescrire International 2020; 29 (218): 214. Free.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >